Wave Life Sciences
WVE
NASDAQ
IPO2015
about WVE
Wave Life Sciences is a clinical-stage biotechnology company that utilizes its proprietary PRISM platform and stereopure oligonucleotide chemistry to design and develop RNA medicines - including editing, silencing, and splicing therapies - to precisely target the genetic causes of both rare diseases (like Huntington's and Duchenne Muscular Dystrophy) and prevalent disorders (like obesity and Alpha-1 Antitrypsin Deficiency).
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $12.82 | $19.60 | $12.72 | $1.25B | 147.25M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$0.32 | n/a | n/a | -740.71% | -707.83% | 0% |